Today’s Price Action: What Will Happen to Aquinox Pharmaceuticals Inc Next? The Stock Just Increased A Lot

Today's Price Action: What Will Happen to Aquinox Pharmaceuticals Inc Next? The Stock Just Increased A Lot

The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is a huge mover today! The stock increased 8.68% or $1.16 during the last trading session, hitting $14.52. About 449,831 shares traded hands or 2.36% up from the average. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 50.28% since February 29, 2016 and is uptrending. It has outperformed by 38.07% the S&P500.
The move comes after 8 months positive chart setup for the $321.36 million company. It was reported on Oct, 3 by We have $40.08 PT which if reached, will make NASDAQ:AQXP worth $565.59 million more.

Analysts await Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to report earnings on November, 8. They expect $-0.62 EPS, down 44.19% or $0.19 from last year’s $-0.43 per share. After $-0.63 actual EPS reported by Aquinox Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -1.59% EPS growth.

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage

Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The rating was initiated by Leerink Swann with “Outperform” on Monday, September 21. Jefferies maintained the stock with “Hold” rating in Friday, August 5 report. Needham initiated Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) rating on Friday, October 23. Needham has “Buy” rating and $25 price target. On Friday, September 11 the stock rating was maintained by Canaccord Genuity with “Hold”. The rating was maintained by Jefferies with “Hold” on Tuesday, March 15. The firm earned “Buy” rating on Tuesday, October 6 by Guggenheim.

According to Zacks Investment Research, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.”

More important recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: which released: “Aquinox Pharma (AQXP) Appoints New Chief Medical Officer” on October 03, 2016, also published article titled: “Aquinox Pharmaceuticals stock skyrockets 450%”, published: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. More interesting news about Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) was released by: and their article: “Aquinox Pharmaceuticals Inc (AQXP): How This Biotech Stock Trapped Investors” with publication date: August 17, 2015.

AQXP Company Profile

Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment